⌘K
Loading ticker…
As of 2026-08-24, The Chemours Company (CC) has a 3-month relative strength percentile of 15 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 47. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.8%, relative volume 0.49×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
CC is in a stage 3 topping pattern, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -14.3% / -14.4%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
CC is held by 31 ETFs as of May 2026. Top owner: AVUV at 0.28% weight, $77M notional. Top 3 carry $110M.
Held by 82 ETFs · $925M across latest filings · largest weight 4.35% (PSCM).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| AVUVAvantis U.S. Small Cap Value ETF | 0.28% | $77M | — |
| VTWO | 0.10% | $17M | — |
| SCHASchwab U.S. Small-Cap ETF | 0.07% | $16M | — |
| VIOOVanguard S&P Small-Cap 600 ETF | 0.20% | $12M | +0.02 pp |
| VAWVanguard Materials ETF |
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Related searches
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.21% |
| $10M |
| +0.05 pp |
| FNDXSchwab Fundamental U.S. Large Company Index ETF | 0.03% | $9M | — |
| RWJ | 0.43% | $8M | −0.12 pp |
| VIOVVanguard S&P Small-Cap 600 Value ETF | 0.39% | $7M | +0.04 pp |
| AVSC | 0.24% | $7M | +0.04 pp |
| AVUSAvantis U.S. Equity ETF | 0.02% | $3M | — |
Showing 10 of 31 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CC Jan avg: 13.50% median: 15.60% win: 75% σ: 13.35% n: 4 2022-04-12 → 2026-07-31 | CC Feb avg: -10.12% median: -13.67% win: 25% σ: 24.23% n: 4 2022-04-12 → 2026-07-31 | CC Mar avg: 8.09% median: 5.64% win: 50% σ: 22.63% n: 4 2022-04-12 → 2026-07-31 | CC Apr avg: 2.95% median: 1.87% win: 60% σ: 11.65% n: 5 2022-04-12 → 2026-07-31 | CC May avg: -4.35% median: -8.88% win: 20% σ: 20.00% n: 5 2022-04-12 → 2026-07-31 | CC Jun avg: 2.03% median: -7.40% win: 40% σ: 24.94% n: 5 2022-04-12 → 2026-07-31 | CC Jul avg: 0.81% median: 4.63% win: 80% σ: 11.79% n: 5 2022-04-12 → 2026-07-31 | CC Aug avg: -1.06% median: -6.62% win: 25% σ: 20.70% n: 4 2022-04-12 → 2026-07-31 (current) | CC Sep avg: -9.27% median: -7.35% win: 50% σ: 15.47% n: 4 2022-04-12 → 2026-07-31 | CC Oct avg: -6.00% median: -12.34% win: 25% σ: 14.90% n: 4 2022-04-12 → 2026-07-31 | CC Nov avg: 9.36% median: 11.11% win: 75% σ: 10.31% n: 4 2022-04-12 → 2026-07-31 | CC Dec avg: -4.12% median: -4.60% win: 25% σ: 15.44% n: 4 2022-04-12 → 2026-07-31 |